MAPT and Alzheimer disease: A novel study that aimed to discover prior combinations of AD biomarkers developed six highly sensitive immunoassays detecting Tau(1–22)-pTau231, Tau(1–22)-pTau217, and Tau(1–22)-pTau181 on ultra-sensitive simoa platform with LOD at picomolar level31.